Back to search results
NCT07286006

A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)

Enrolling by Invitation
PHASE2Ages 18+InterventionalTreatment
Immunovant Sciences GmbH
~372 participants
Updated 2026-07-27 on ClinicalTrials.gov
What's tested:IMVT-1402

At a glance

Recruiting sites
0 of 105 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percentage of Group A Participants who remain euthyroid, Off ATD, and Off IMVT-1402
Measured over At Week 52

Conditions

Graves' Disease

Explore related trials

Graves DiseaseCBR1 wt Allele

NCT07286006

Where you'd take part

This study runs at 105 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Site Number - 1500

    Morehead City, North Carolinano site contact published

  • Site Number - 1501

    Mesquite, Texasno site contact published

  • Site Number - 1502

    El Paso, Texasno site contact published

  • Site Number - 1503

    Farmington Hills, Michiganno site contact published

  • Site Number - 1504

    Fort Worth, Texasno site contact published

  • Site Number - 1505

    Miami, Floridano site contact published

  • Site Number - 1506

    Hickory, North Carolinano site contact published

  • Site Number - 1507

    Port Charlotte, Floridano site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participants who completed Study IMVT-1402-2502 or Study IMVT-1402-2503.

Exclusion

Have permanently discontinued IMP during the treatment period in the feeder study or have met study stopping criteria at any point up until the end of participation in the feeder study.

What this trial measures

  • Percentage of Group A Participants who remain euthyroid, Off ATD, and Off IMVT-1402At Week 52